A magisterial survey of all aspects of the reverse transcriptase inhibitors (RTIs) used to treat HIV/AIDS, including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development of eight nucleoside and nucleotide analogs that represent milestones in treatment history, and thoroughly discuss the question of toxicity and resistance to this class of drugs. They also address three non-nucleoside RTIs and their pharmacokinetics and comparative clinical efficacy, new RTIs currently under development, and the impact of approved agents on treatment, in general, and on vertical transmission in the developing world.
Reviews
From the reviews:
"This book will appeal to medical students needing a detailed review of area … . It is most suitable for libraries … . The individual chapters are authoritative and comprehensive … . a source for in-depth and specific information." (Mark Harris, Microbiology Today, November, 2006)
Editors and Affiliations
National Institute of Allergy and Infectious Diseases National Institutes of Health, USA
Vassil St.Georgiev
Division of Infectious Diseases, Roger Williams Medical Center, Providence
Gail Skowron
Boston University School of Medicine, Boston
Gail Skowron
Pfizer Inc., San Diego
Richard Ogden
Center for Poverty-Related Communicable Diseases Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Joep M. A. Lange
Bibliographic Information
Book Title: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy
Editors: Vassil St.Georgiev, Gail Skowron, Richard Ogden, Joep M. A. Lange
